Against some tough competition, MDC was recognised as a key enabler of life science innovation, acknowledging its work to build innovation ecosystems and the impactful strategies it develops to engage with the community.
MDC has helped UK companies raise almost £900m in private funding, supported over 240 partners and created six strategic, high-impact R&D national programmes across Antimicrobial Resistance (AMR), Psychiatry, Dementia, Cystic Fibrosis, Total Body Imaging and Complex Medicines. It also delivered the largest laboratory diagnostics project in UK history – the UK Lighthouse Laboratory Network, which tested over 150m PCR samples during the Covid-19 pandemic.
Earlier this week, it was announced that MDC is a delivery partner for the Government’s Dame Barbara Windsor Dementia Mission. By supporting the launch of the Mission, MDC will ensure it is able to deliver a transformative, industry-enabling approach to dementia research.
Professor Chris Molloy, CEO of Medicines Discovery Catapult, said: “MDC’s foundation is built on excellence, integrity, community, and innovation, and we are pleased this has been commended by One Nucleus. We will continue to support and champion our sector to give innovators access to our world-class facilities and expertise, ensuring that we play our part in reshaping drug discovery for patient benefit.”
One Nucleus is a not-for-profit Life Sciences and Healthcare organisation which supports institutions, companies and individuals in the Life Sciences sector to provide local, UK-wide and international connectivity.
PACE (Pathways to Antimicrobial Clinical Efficacy) and the UK Health Security Agency (UKHSA) have released five new contemporary antimicrobial resistance (AMR) strain panels, giving innovators worldwide a resource to test novel therapeutics and diagnostics against today’s resistance patterns.
New appointments support MDC’s mission to turn drug discovery into commercial breakthroughs.
